NeuCyte Licenses Its Novel Neuronal Programming Technology to Enable Academic Research
As part of the agreement, Boston Children's has obtained a non-exclusive license from NeuCyte to manufacture transcription factor Ngn2 programmed induced neurons.
- As part of the agreement, Boston Children's has obtained a non-exclusive license from NeuCyte to manufacture transcription factor Ngn2 programmed induced neurons.
- The hospital intends to use this technology for internal research, teaching and educational purposes, and to perform services to other academic institutions.
- "NeuCyte has the exclusive rights to Stanford's original neuronal induction technology and has further developed it to incorporate intoour proprietary in vitro drug discovery platforms," said Jonathan Davila, PhD, Co-founder and CEO of NeuCyte.
- "We are happy to get the technology into the hands of Boston Children's Hospital where it can be further used for academic research.